FDA Rejects Generic Autism Drug Despite Trump Administration Pressure

In September, the president promised a treatment for autism. In March, the FDA delivered something very different — and families are paying the price.

The Announcement That Changed Everything

On September 22, 2025, President Donald Trump and Health and Human Services Secretary Robert F. Kennedy Jr. stood at the White House and delivered what sounded like transformative news for millions of American families. The FDA, they announced, was moving to approve leucovorin — a cheap, decades-old generic form of vitamin B9 — as a treatment for children with autism spectrum disorder [1][2].

FDA Commissioner Marty Makary, who had been appointed by Trump earlier that year, was emphatic. In a Politico op-ed reposted on the White House website, Makary wrote that his agency would "approve prescription leucovorin as a treatment for children with cerebral folate deficiency and autistic symptoms." He went further in public remarks, suggesting that "it might be 20, 40, 50% of kids with autism" could benefit [3][4].

For the roughly 1 in 31 American children now identified with autism spectrum disorder — a rate that represents a 384% increase since 2000, according to the CDC — the announcement felt seismic [5]. Kennedy, who had pledged months earlier to determine the cause of autism by September, framed the leucovorin initiative as a down payment on that promise [6].

What the FDA Actually Approved

Six months later, on March 10, 2026, the FDA delivered its verdict — and it bore almost no resemblance to the White House's September fanfare.

The agency approved Wellcovorin (leucovorin calcium) tablets for the treatment of cerebral folate transport deficiency caused by a variant in the FOLR1 gene, known as CFD-FOLR1. It is the first FDA-approved treatment for this condition [7][8].

There was one problem: CFD-FOLR1 is an ultra-rare genetic disorder estimated to affect fewer than one in a million people. Fewer than 50 cases have ever been identified worldwide [9]. It was not an approval for autism.

"We don't have sufficient data to say that we could establish efficacy for autism more broadly," a senior FDA official told reporters in a briefing the day before the announcement [3][10].

Alycia Halladay, chief science officer at the Autism Science Foundation, said the actual approval was "1,000% different" from what was promised in September [11]. David Mandell, a psychiatry professor at the University of Pennsylvania, called the original messaging "terrible for families," adding that they "deserve more careful science. They deserve more accurate information" [11].

Source: GDELT Project

Data as of Mar 11, 2026CSV

The Science That Wasn't There

The gap between the White House's September promise and the FDA's March decision can be traced, in part, to a single study — one that no longer exists in the scientific record.

The largest randomized, double-blind, placebo-controlled trial ever conducted to test leucovorin's efficacy in children with autism was retracted in January 2026 by the European Journal of Pediatrics. Originally published in September 2024, the study had claimed that 24 weeks of daily treatment with oral folinic acid reduced symptom severity in autistic children compared to a placebo. But independent researchers found that numbers in the data tables did not add up, and the journal confirmed it was "unable to replicate the results reported in the article from the dataset provided" [12][13].

The retraction was devastating for the scientific case behind leucovorin as an autism treatment. Without it, the remaining evidence consists of small, preliminary studies with middling results — far below the threshold the FDA typically requires for drug approval [10][13].

The FDA officials who briefed reporters acknowledged the retraction directly, noting it had weakened an already thin evidence base. The American Academy of Pediatrics does not recommend routine use of leucovorin for autistic children [3]. And Dr. Alycia Halladay of the Autism Science Foundation put it bluntly: "There is no evidence to say that leucovorin will help most people with autism, and there's certainly no evidence to say it's safe" [4].

For its part, the FDA based its narrow CFD-FOLR1 approval not on a clinical trial but on a systematic review of published literature, including case reports. Among 27 patients with the confirmed genetic variant who were treated with oral leucovorin alone, 24 — or 89% — demonstrated clinically meaningful neurological improvements [7][8]. The evidence was strong for that tiny population. It simply did not extend to autism more broadly.

The Prescription Surge and Its Consequences

The September White House announcement had immediate, measurable consequences in doctors' offices and pharmacies across the country.

A study published in The Lancet in early March 2026 found that leucovorin prescriptions for children aged 5 to 17 surged 71% above normal levels in the three months following the September news conference [3][14]. Some analyses found that new prescriptions for the drug doubled outright [11]. Dr. Jeremy Faust, an emergency medicine physician at Brigham and Women's Hospital and the study's author, noted that the evidence for leucovorin as an autism treatment was thin and "didn't warrant a shift in practice" — but he wasn't surprised to see prescriptions spike given the high-profile endorsement [14].

The demand surge created what drug supply experts describe as a demand-side shortage. Most manufacturers of leucovorin placed tablets on allocation or backorder, rationing existing supplies and limiting how much pharmacies could order [15]. Families whose children had been taking leucovorin for its established uses — including as a counteragent to chemotherapy side effects — suddenly found themselves unable to fill prescriptions.

Parents of autistic children, meanwhile, described complicated, often fruitless searches for providers and pharmacies that could supply the drug. Some turned to unregulated over-the-counter folate supplements as substitutes, raising additional safety concerns [15][14].

Source: GDELT Project

Data as of Mar 11, 2026CSV

A Pattern of Premature Promises

The leucovorin episode fits within a broader pattern of the Trump administration making sweeping health claims that outpace the underlying science.

At the same September 2025 news conference, Trump suggested a link between Tylenol (acetaminophen) and autism — a claim that public health experts immediately challenged as unsupported by robust evidence [6]. Kennedy's pledge to identify the cause of autism by September was itself viewed with deep skepticism by the scientific community, given that autism spectrum disorder is understood to involve complex interactions between genetic and environmental factors that have resisted simple causal explanations for decades [6].

The administration's interest in leucovorin reportedly originated from consultations with an Arizona neurologist who prescribes the drug and runs an online education business about the treatment [3] — a provenance that raised additional questions about the rigor of the policy process.

Currently, only two drugs have ever received FDA approval for any aspect of autism: risperidone (Risperdal), approved in 2006, and aripiprazole (Abilify), approved in 2009. Both are approved solely for the treatment of irritability associated with ASD — not for the core symptoms of the disorder [16]. No medication has ever been approved to treat autism's core characteristics, and the mainstays of treatment remain behavioral therapy and educational interventions.

What Happens Now

Despite the FDA's decision not to approve leucovorin for autism, doctors can still prescribe the drug off-label for that purpose — and many likely will. Off-label prescribing is legal and common in medicine, though it means the drug has not been shown to be effective for that use through the FDA's standard review process.

The FDA noted that the National Institutes of Health had launched confirmatory clinical trials to study leucovorin's potential benefits for autism more rigorously [1]. Those trials, if completed, could eventually provide the evidence base that is currently lacking. But clinical trials take years, and early indications are "not coming back promising," according to reporting from NBC News [11].

For the families who rushed to obtain leucovorin prescriptions after the September announcement, the FDA's March decision presents a painful reckoning. Many spent months navigating shortages and paying out of pocket for a treatment the FDA now says lacks sufficient evidence. The episode illustrates the real-world consequences when political timelines collide with scientific ones — and when the bully pulpit of the White House is deployed before the evidence is in.

The Broader Stakes

The leucovorin saga raises fundamental questions about the relationship between political leadership and scientific regulatory agencies. The FDA exists, in part, as an independent check — a body that evaluates evidence according to established scientific standards, regardless of political pressure. When the White House pre-announces an approval that the FDA's own scientists cannot support, it undermines public trust in both institutions.

Autism advocacy organizations have expressed frustration from multiple angles. Some families feel the government raised and then dashed their hopes. Others worry that the controversy has distracted from more promising, evidence-based research into autism treatments and support services. And the drug shortage created by the demand surge has caused real harm to patients who depend on leucovorin for other, well-established medical uses.

As the dust settles on the FDA's decision, one fact remains unchanged: autism spectrum disorder affects more American children than ever, and there is still no FDA-approved treatment for its core symptoms. The families waiting for real answers deserve better than premature announcements and quiet walkbacks.